Reducing morbidity in respiratory tract infections

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1232, 2000-01, pp. : 17-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Moxifloxacin in respiratory tract infections

By Miravitlles Marc  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 2, 2005-02 ,pp. : 283-293

Informa Healthcare

Access to resources Recommend Favorite

Azithromycin and lower respiratory tract infections

By Blasi F   Cazzola M   Tarsia P   Cosentini R   Aliberti S   Santus P   Allegra L  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 13, 2005-10 ,pp. : 2335-2351

Informa Healthcare

Access to resources Recommend Favorite

Lower Respiratory Tract Infections: Impact on the Workplace

By Birnbaum H.G.  

PharmacoEconomics, Vol. 21, Iss. 10, 2003-01 ,pp. : 749-759

Adis International

Access to resources Recommend Favorite

Telithromycin: an innovative solution to resistance in respiratory tract infections

By  

Inpharma, Vol. 1, Iss. 1261, 2000-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

EDP 420 has potential for respiratory tract infections

By  

Inpharma, Vol. 1, Iss. 1608, 2007-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite